4.1.1 Even as significant advances have been made in discrete technologies and process unit operations, considerable inefficiencies remain in the manufacture of recombinant biopharmaceuticals, resulting in suboptimal “time in plant” and facility throughput. Upstream and downstream processing capacities within and across facilities frequently fall into imbalance owing to the diversity of required custom processes, differences in productivity of cellular expression systems, and the nature of the product feed stream being delivered for purification. In addition, the frequent need to employ multi-vendor equipment across the process flow creates additional inefficiencies. In essence, these dynamics generate continual processing bottlenecks.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.2.1 Supporting all the above-mentioned advances in bioprocessing technologies is the digital revolution. The biopharmaceutical manufacturing industry, supported by numerous specialist vendors, is now overcoming its initial reluctance to adopt electronic batch records (driven largely by validation and Title 21 Code of Federal Regulations [CFR] part 11 concerns). Continuing regulatory focus on data integrity during bioprocessing is accelerating the adoption of broad electronic documentation systems, laboratory information management systems (LIMS), and supply chain management and tracking.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
4.3.1 One of the ongoing challenges in the biomanufacturing industry is a serious labor shortage. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public–private partnership that was founded in 2017 to study, highlight, and address the challenges in the industry.[97] In 2022, NIIMBL published a study in which they surveyed manufacturers across the U.S. and found the talent shortage to be ubiquitous.[98] While the shortage is felt across all levels of biomanufacturing organizations, it is striking that only 42% of job postings for manufacturing associates require a bachelor’s degree.[98] Traditionally, firms across industries will pay relocation fees for high-level employees such as managers and above, but relocation support for entry-level employees without a college degree is rare. Companies are left, then, to recruit from local talent for entry-level manufacturing associates jobs while they simultaneously compete nationally (or even globally) for more educated talent.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.